As of Friday close, Impel Pharmaceuticals Inc.’s (NASDAQ:IMPL) stock was down -$0.25, moving down -39.73 percent to $0.38. The average number of shares traded per day over the past five days has been 534,620 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.8173 fall in that time frame. In the last twenty days, the average volume was 173,570, while in the previous 50 days, it was 895,596.
Since last month, IMPL stock retreated -76.66%. Shares of the company fell to $0.3703 on 08/18/23, the lowest level in the past month. A 52-week high of $8.05 was reached on 01/04/23 after having rallying from a 52-week low of $0.54. Since the beginning of this year, IMPL’s stock price has dropped by -89.79% or -$3.3673, and marked a new high 2 times. However, the stock has declined by -95.25% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended March 30, Impel Pharmaceuticals Inc.’s quick ratio stood at 2.00, while its current ratio was 2.30, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 55.10% percent. Based on annual data, IMPL earned $6.16 million in gross profit and brought in $12.65 million in revenue.
In Impel Pharmaceuticals Inc.’s quarter-end financial report for March 30, it reported total debt of $48.1 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. IMPL’s revenue rose 59.73% to -$7.31 million during the quarter, while net income inched up to $4.37 million. While analysts expected Impel Pharmaceuticals Inc. to report -$0.9 quarterly earnings, the actual figure was -$1.27 per share, beating the consensus estimate by -41.10%. During the quarter, the company generated -$24.16 million in EBITDA. The liabilities of Impel Pharmaceuticals Inc. were 137.63 million at the end of its most recent quarter ended March 30, and its total debt was $119.78 million. The value of shareholders’ equity is $23.75 million.
Technical Picture
This quick technical analysis looks at Impel Pharmaceuticals Inc.’s (IMPL) price momentum. With a historical volatility rate of 332.92%, the RSI 9-day stood at 13.50% on 18 August.
With respect to its five-day moving average, the current Impel Pharmaceuticals Inc. price is down by -68.11% percent or -$0.8173. At present, IMPL shares trade -75.78% below its 20-day simple moving average and -69.14% percent below its 100-day simple moving average. However, the stock is currently trading approximately -70.45% below its SMA50 and -90.21% below its SMA200.
Stochastic coefficient K was 6.22% and Stochastic coefficient D was 6.11%, while ATR was 0.2192. Given the Stochastic reading of 1.11% for the 14-day period, the RSI (14) reading has been calculated as 20.38%. As of today, the MACD Oscillator reading stands at -0.4514, while the 14-day reading stands at -0.5565.
Analyst Ratings
Wedbush launched its rating on Impel Pharmaceuticals Inc. (NASDAQ: IMPL) to an Outperform in a note to investors on May 18, 2021. Impel Pharmaceuticals Inc. (IMPL) has been rated Overweight by analysts. According to 0 brokerage firms, IMPL is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Impel Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $25.00, the current consensus forecast for the stock is $10.00 – $40.00. Based on these forecasts, analysts predict Impel Pharmaceuticals Inc. (IMPL) will achieve an average price target of $25.00.
